Edwards Lifesciences Corporation
EW.SW
Swiss Exchange188.26
CHF
- -
- -
Edwards Lifesciences Corporation
EW.SW
(Swiss Exchange)
Recent
price
188.26
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Edwards Lifesciences Corporation (NYSE: EW) develops, manufactures and markets innovative medical technologies for structural heart disease and critical care; the company specializes in transcatheter heart valves including the SAPIEN family for aortic stenosis and the forthcoming JenaValve Trilogy for aortic regurgitation, transcatheter mitral and tricuspid technologies such as EVOQUE, surgical valve technologies encompassing INSPIRIS RESILIA bioprosthetic valves and repair products, and hemodynamic monitoring systems like the EV1000 platform with Acumen IQ sensors; prior to its divestiture, the critical care segment offered pulmonary artery catheters, pressure transducers and vascular products. Founded in 1958 by Miles Lowell Edwards and Dr. Albert Starr and headquartered in Irvine, California, the company operates manufacturing facilities in Utah, Costa Rica, the Dominican Republic, Puerto Rico, Singapore and Ireland, with sales serving patients in over 100 countries across North America, Europe, Japan and other regions. In recent developments, Edwards sold its critical care business to BD for $4.2 billion in 2024 to sharpen focus on structural heart innovation, completed acquisitions of JenaValve Technology and Endotronix for approximately $1.2 billion upfront in 2024 to expand into aortic regurgitation and heart failure management with the FDA-approved Cordella sensor, acquired Innovalve for $300 million to bolster mitral valve capabilities, announced a $500 million accelerated share repurchase in August 2025 bringing total repurchases over $800 million that year, and projects steady growth in transcatheter aortic valve replacement and transcatheter mitral/tricuspid therapies into 2025.